On October 31, 2022 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open (Press release, Compugen, OCT 31, 2022, View Source [SID1234622657]). Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the update, management will discuss Compugen’s data to be presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), being held on November 8-12, 2022.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S.,
or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen’s website, located at the following link

Following the live webcast, a replay will be available on the Company’s website.